3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
8
avelumab
6
fludarabine
3
Radiotherapy
3
Radiation
3
Cyclophosphamide
3
cemiplimab
2
atezolizumab
2
aldesleukin
2
Interleukin-2
2
Interferon-beta
2
ALT-803
2
talimogene laherparepvec
1
poly ICLC
1
pentetreotide
1
interferon gamma-1b
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
cabozantinib
1
bempegaldesleukin
1
TTI-621
1
Paclitaxel
1
Nivolumab
1
Interferon-gamma
1
Influenza Vaccines
1
Immunotherapy
1
High-Intensity Focused Ultrasound Ablation
1
Carboxylesterase
1
B7-H1 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Merkel Cell
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled